All Oncology News

Tafasitamab plus lenalidomide and rituximab improved progression-free survival vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Investigators are developing preventive interventions to identify patients most at risk for financial toxicity and offer them assistance.

Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Researchers at Fox Chase Cancer Center have identified factors that could decrease incidence of prostate cancer in areas where rates are highest.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes. 

The FDA has approved axatilimab for adult and pediatric patients with cGVHD who have progressed on at least 2 prior lines of systemic therapy.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

Durvalumab plus chemotherapy, then durvalumab with or without olaparib, was approved in Europe for select advanced/recurrent endometrial cancer.

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Mohamad Mohty, MD, PhD, discusses real-world data for elranatamab in relapsed/refractory multiple myeloma in the French compassionate use program.

Fox Chase Cancer Center announces Aitziber Buque Martinez, PhD, as an assistant professor in the Cancer Signaling and Microenvironment Research Program.

Enrollment will discontinue for the SELECT-AML-1 trial of tamibarotene/venetoclax/azacitidine in newly diagnosed, RARA-positive acute myeloid leukemia.

Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.